Thompson plans to transition into the position of EVP and chief medical officer. As a result, the company appointed Dr. John Liddicoat as its new president and CEO, effective immediately.
Richard Mott, Endologix’s board chair, said in a news release that the change comes as Thompson seeks to spend more time in the U.K.
Endologix, based in Irvine, California, develops technologies for treating artery disease. That includes the Detour system for treating peripheral arterial disease (PAD).
Liddicoat has more than 30 years of global healthcare experience, including serving on the boards of several medtech companies. He spent more than 16 years in executive roles at Medtronic. There, he led strategic initiatives and oversaw global operations for divisions that included cardiac rhythm and heart failure.
“We are thrilled to welcome Dr. John Liddicoat as our new CEO,” said Mott. “John’s extensive experience and proven leadership in the healthcare industry make him the ideal person to guide Endologix through its next chapter of growth and innovation. I also want to extend our sincere appreciation to Matt for his exceptional leadership and the significant advancements he has brought to Endologix during his tenure as CEO. We are pleased that Matt will remain an integral part of our team, enabling him to balance his professional commitments with a desire to spend more time in the U.K.”
